Amylx Pharmaceuticals Inc vs iShares Core Growth Allocation ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while iShares Core Growth Allocation ETF trades at $70.12. Which is the better fit depends on your goals.
| AMLX | AOR | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $70.12 |
52-Week Low | $7.82 | $62.26 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
AOR, the iShares Core Growth Allocation ETF, trades at $69.87, showing minimal daily movement. Technical indicators are bullish based on moving averages, though the RSI suggests potential overbought conditions. The fund maintains a fixed 60/40 stock/bond allocation, offering a low-cost, diversified core holding strategy with a 20 basis point fee.
The outlook for AOR is stable, providing a straightforward asset allocation tool for long-term investors. Key risks include underperformance versus pure equity indices like the S&P 500 over extended periods, as noted by financial media, and sensitivity to interest rate changes affecting the bond portion.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →